Target Name: ASCC3
NCBI ID: G10973
Review Report on ASCC3 Target / Biomarker Content of Review Report on ASCC3 Target / Biomarker
ASCC3
Other Name(s): ASC-1 complex subunit P200 | dJ121G13.4 | ASC-1 complex subunit p200 | HELIC1 | Activating signal cointegrator 1 complex subunit 3 | OTTHUMP00000016905 | activating signal cointegrator 1 complex subunit 3 | DJ467N11.1 | ASCC3_HUMAN | Helicase, ATP binding 1 | helicase, ATP binding 1 | MGC26074 | B630009I04Rik | RNA helicase family | ASCC3 variant 1 | Activating signal cointegrator 1 complex subunit 3, transcript variant 1 | RNAH | Activating signal cointegrator 1 complex subunit 3 (isoform a) | Trip4 complex subunit p200 | ASC1p200 | trip4 complex subunit p200

ASCC3: A Potential Drug Target Or Biomarker

ASCC3 (ASC-1 complex subunit P200) is a protein that is expressed in various tissues and cells throughout the body. It is a key component of the ASC-1 complex, which is a protein complex that is involved in a variety of cellular processes , including cell signaling, cell division, and tissue development.

Recent studies have suggested that ASCC3 may be a drug target or biomarker, due to its involvement in these cellular processes. In this article, we will explore the potential role of ASCC3 in drug development and use it as an indicator for the development of new therapeutic approaches.

The ASC-1 complex is a protein complex that is composed of several different subunits, including ASC-1A, ASC-1B, and ASC-1C. These subunits are involved in a variety of cellular processes, including cell signaling, cell division, and tissue development.

ASCC3 is a key component of the ASC-1 complex, and is involved in the regulation of several cellular processes. It plays a role in the regulation of cell signaling, by interacting with the protein PDGF-BB. This interaction between ASCC3 and PDGF- BB allows for the regulation of cell signaling, and is a potential target for drug development.

In addition to its role in cell signaling, ASCC3 is also involved in the regulation of cell division. It plays a role in the regulation of mitosis, by interacting with the protein MENIN. This interaction between ASCC3 and MENIN allows for the regulation of cell division , and is a potential target for drug development.

ASCC3 is also involved in the regulation of tissue development, by interacting with the protein social development. This interaction between ASCC3 and social development allows for the regulation of tissue development, and is a potential target for drug development.

In conclusion, ASCC3 is a protein that is involved in several cellular processes, including cell signaling, cell division, and tissue development. Its involvement in these processes makes it a potential drug target or biomarker, and its potential targets are the focus of ongoing research in the field of drug development.

Protein Name: Activating Signal Cointegrator 1 Complex Subunit 3

Functions: 3'-5' DNA helicase involved in repair of alkylated DNA (PubMed:22055184). Promotes DNA unwinding to generate single-stranded substrate needed for ALKBH3, enabling ALKBH3 to process alkylated N3-methylcytosine (3mC) within double-stranded regions (PubMed:22055184). Also involved in activation of the ribosome quality control (RQC) pathway, a pathway that degrades nascent peptide chains during problematic translation (PubMed:28757607, PubMed:32099016). Drives the splitting of stalled ribosomes, as part of the ribosome quality control trigger (RQT) complex (PubMed:28757607, PubMed:32099016). Part of the ASC-1 complex that enhances NF-kappa-B, SRF and AP1 transactivation (PubMed:12077347)

The "ASCC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASCC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ASCL1 | ASCL3 | ASCL4 | ASCL5 | ASF1A | ASF1B | ASGR1 | ASGR2 | ASH1L | ASH1L-AS1 | ASH2L | Asialoglycoprotein receptor | Asialoglycoprotein Receptor (ASGPR) | ASIC1 | ASIC2 | ASIC3 | ASIC4 | ASIC5 | ASIP | ASL | ASMER1 | ASMER2 | ASMT | ASMTL | ASMTL-AS1 | ASNS | ASNSD1 | ASNSP1 | ASPA | ASPDH | ASPG | ASPH | ASPHD1 | ASPHD2 | ASPM | ASPN | ASPRV1 | ASPSCR1 | ASRGL1 | ASS1 | ASS1P1 | ASS1P10 | ASS1P11 | ASS1P12 | ASS1P13 | ASS1P2 | ASS1P4 | ASS1P5 | ASS1P6 | ASS1P7 | ASS1P9 | ASTE1 | ASTL | ASTN1 | ASTN2 | ASTN2-AS1 | Astrin complex | ASXL1 | ASXL2 | ASXL3 | ASZ1 | AT-Rich interactive domain-containing protein | ATAD1 | ATAD2 | ATAD2B | ATAD3A | ATAD3B | ATAD3C | ATAD5 | ATAT1 | ATCAY | ATE1 | ATE1-AS1 | ATF1 | ATF2 | ATF3 | ATF4 | ATF4P2 | ATF4P4 | ATF5 | ATF6 | ATF6-DT | ATF6B | ATF7 | ATF7IP | ATF7IP2 | ATG10 | ATG101 | ATG12 | ATG13 | ATG14 | ATG16L1 | ATG16L2 | ATG2A | ATG2B | ATG3 | ATG4A | ATG4B | ATG4C | ATG4D